Yang Hengli, Zhao Ping, Zhou Yonggang, Li Qiaoying, Cai Wenbin, Zhao Zongxia, Shen Jian, Yao Kechun, Duan Yunyou
Department of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi'an, China.
Department of Ultrasound Diagnosis, The Second Affiliated Hospital, Xi'an Medical College, Xi'an, China.
Sci Rep. 2021 Mar 18;11(1):6254. doi: 10.1038/s41598-021-82602-9.
Pancreatic cancer will gradually become the second leading cause of cancer death due to its poor suitability for surgical treatment, frequent recurrence and metastasis, and insensitivity to radiotherapy and chemotherapy. Strategies for precise early detection and effective targeted treatment of pancreatic cancer are urgently needed. Because of its unique advantages, molecular targeted contrast-enhanced ultrasound imaging (CEUI) has generated new opportunities to overcome this challenge. The aim of this study was to explore multifunctional nanobubbles named IR780-NBs-DTX as novel ultrasound contrast agents (UCAs) for dual-mode targeted imaging and photothermal ablation combined with chemotherapy for pancreatic cancer. An optimized "film hydration method" was used to prepare IR780-NBs-DTX in this research. The characteristics and ability of the new UCAs were detected via in vitro, in vivo and ex vivo experiments. The initial dose of 0.15 mg IR-780 iodide/1.0 mg DTX was considered to be the best formula for IR780-NBs-DTX, and the concentration of 6 ×10 bubbles/mL was best for CEUI. The excellent characteristics of IR780-NBs-DTX, including a uniform nanoscale particle size (349.8± 159.1 nm, n= 3), good performance in dual-mode imaging, high stability and reliable biocompatibility, were also proven. In the in vitro cell experiments, IR780-NBs-DTX targeted more pancreatic cancer cells than the control treatments, and the targeting rate was approximately 95.6± 1.7%. Under irradiation with an 808 nm laser, most cells died. Furthermore, the in vivo study demonstrated that IR780-NBs-DTX could precisely detect pancreatic cancer through near infrared fluorescence (NIRF) imaging and CEUI, and the tumor almost disappeared at 18 days after combined treatment. In ex vivo experiments, immunohistochemistry (IHC) and immunofluorescence (IF) showed that the expression of HSP70 increased and that of PCNA decreased, and many apoptotic tumor cells were observed by TUNEL staining in the IR780-NBs-DTX group. The newly prepared IR780-NBs-DTX are novel nanosized UCAs with high efficiency for dual-mode molecular targeted imaging and combined therapy, and they may have future potential applications in the precise detection and effective targeted therapy of small and metastatic lesions in the early stage of pancreatic cancer.
由于胰腺癌手术治疗适应性差、复发和转移频繁以及对放疗和化疗不敏感,它将逐渐成为癌症死亡的第二大主要原因。因此,迫切需要精确早期检测和有效靶向治疗胰腺癌的策略。分子靶向对比增强超声成像(CEUI)因其独特优势,为克服这一挑战带来了新机遇。本研究旨在探索名为IR780-NBs-DTX的多功能纳米气泡作为新型超声造影剂(UCAs),用于胰腺癌的双模靶向成像、光热消融联合化疗。本研究采用优化的“薄膜水化法”制备IR780-NBs-DTX。通过体外、体内和离体实验检测新型UCAs的特性和能力。0.15 mg碘化IR-780/1.0 mg多西他赛的初始剂量被认为是IR780-NBs-DTX的最佳配方,6×10气泡/mL的浓度最适合CEUI。IR780-NBs-DTX还具有优异特性,包括均匀的纳米级粒径(349.8±159.1 nm,n = 3)、双模成像性能良好、稳定性高和生物相容性可靠。在体外细胞实验中,IR780-NBs-DTX比对照处理靶向更多的胰腺癌细胞,靶向率约为95.6±1.7%。在808 nm激光照射下,大多数细胞死亡。此外,体内研究表明,IR780-NBs-DTX可通过近红外荧光(NIRF)成像和CEUI精确检测胰腺癌,联合治疗18天后肿瘤几乎消失。在离体实验中,免疫组织化学(IHC)和免疫荧光(IF)显示IR780-NBs-DTX组中HSP70表达增加,PCNA表达降低,TUNEL染色观察到许多凋亡肿瘤细胞。新制备的IR780-NBs-DTX是新型纳米级UCAs,具有高效的双模分子靶向成像和联合治疗能力,可能在胰腺癌早期小转移病灶的精确检测和有效靶向治疗中具有未来潜在应用价值。